PriceTargets.com logo

Biohaven - BHVN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $63.00
  • Forecasted Upside: 73.75%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 13 Buy Ratings
  • 1 Strong Buy Ratings
$36.26 As of 12/20/2024 06:31 PM ET
▲ +0.92 (2.60%)

This chart shows the closing price for BHVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biohaven Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHVN

Analyst Price Target is $63.00
▲ +73.75% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Biohaven in the last 3 months. The average price target is $63.00, with a high forecast of $76.00 and a low forecast of $54.00. The average price target represents a 73.75% upside from the last price of $36.26.

This chart shows the closing price for BHVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 14 contributing investment analysts is to buy stock in Biohaven. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
12/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
12/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$58.00 ➝ $61.00
11/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
11/25/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$66.00 ➝ $58.00
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
11/13/2024TD CowenBoost TargetBuy ➝ Buy$55.00 ➝ $75.00
11/13/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$68.00 ➝ $66.00
10/23/2024Cantor FitzgeraldReiterated RatingOverweight
10/4/2024Cantor FitzgeraldReiterated RatingOverweight
10/3/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$55.00 ➝ $68.00
9/24/2024Bank of AmericaBoost TargetBuy ➝ Buy$52.00 ➝ $62.00
9/24/2024Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$55.00 ➝ $66.00
9/24/2024Cantor FitzgeraldReiterated RatingOverweight
9/24/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$59.00 ➝ $68.00
9/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
9/23/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$55.00 ➝ $60.00
9/23/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$58.00 ➝ $60.00
9/23/2024Piper SandlerBoost TargetOverweight ➝ Overweight$66.00 ➝ $76.00
9/16/2024Jefferies Financial GroupInitiated CoverageBuy$57.00
9/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$59.00 ➝ $59.00
9/4/2024Sanford C. BernsteinInitiated CoverageOutperform$55.00
8/30/2024William BlairUpgradeStrong-Buy
8/19/2024Cantor FitzgeraldReiterated RatingOverweight
8/13/2024UBS GroupLower TargetBuy ➝ Buy$55.00 ➝ $54.00
8/12/2024Cantor FitzgeraldReiterated RatingOverweight
7/24/2024Morgan StanleyInitiated CoverageOverweight$58.00
6/18/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$59.00 ➝ $59.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
5/30/2024Cantor FitzgeraldReiterated RatingOverweight
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$63.00 ➝ $59.00
4/23/2024UBS GroupBoost TargetBuy ➝ Buy$59.00 ➝ $60.00
4/18/2024Cantor FitzgeraldReiterated RatingOverweight
4/10/2024Cantor FitzgeraldReiterated RatingOverweight
4/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$61.00
3/4/2024HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $63.00
3/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$62.00 ➝ $61.00
3/1/2024TD CowenBoost TargetOutperform ➝ Outperform$35.00 ➝ $55.00
2/23/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$32.00 ➝ $56.00
2/16/2024Royal Bank of CanadaInitiated CoverageOutperform$62.00
2/6/2024UBS GroupInitiated CoverageBuy$59.00
12/22/2023HC WainwrightInitiated CoverageBuy$50.00
12/8/2023Robert W. BairdInitiated CoverageOutperform$58.00
11/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$26.00 ➝ $32.00
11/15/2023Piper SandlerBoost TargetOverweight ➝ Overweight$29.00 ➝ $36.00
8/16/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$27.00 ➝ $24.00
6/5/2023BTIG ResearchBoost Target$24.00 ➝ $28.00
4/4/2023Cantor FitzgeraldBoost TargetOverweight$27.00 ➝ $31.00
1/24/2023Leerink PartnersReiterated RatingOutperform$24.00
1/24/2023SVB SecuritiesInitiated CoverageOutperform$24.00
1/4/2023JPMorgan Chase & Co.Initiated CoverageOverweight$23.00
12/2/2022BTIG ResearchInitiated CoverageBuy$24.00
11/7/2022CowenSet Target$25.00
11/7/2022CowenLower Target$25.00
10/26/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight$158.00 ➝ $27.00
10/26/2022Piper SandlerLower TargetOverweight$23.00 ➝ $21.00
10/12/2022Piper SandlerInitiated CoverageOverweight$23.00
8/18/2022Piper SandlerDowngradeOverweight ➝ Neutral$149.00
8/8/2022WedbushDowngradeOutperform ➝ Neutral$148.50
5/24/2022Piper SandlerLower TargetNA$156.00 ➝ $149.00
5/11/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
5/11/2022HC WainwrightDowngradeBuy ➝ Neutral
5/11/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$150.00
4/6/2022Morgan StanleyLower TargetEqual Weight$148.00 ➝ $146.00
3/3/2022MizuhoBoost TargetBuy$144.00 ➝ $154.00
1/7/2022HC WainwrightReiterated RatingBuy$160.00
1/7/2022Morgan StanleyBoost TargetEqual Weight$145.00 ➝ $148.00
1/4/2022UBS GroupBoost Target$150.00 ➝ $160.00
12/7/2021HC WainwrightReiterated RatingBuy$160.00
11/18/2021MizuhoBoost TargetPositive ➝ Buy$135.00 ➝ $144.00
11/10/2021Cantor FitzgeraldBoost TargetOverweight$165.00 ➝ $177.00
11/10/2021MizuhoLower TargetBuy$137.00 ➝ $135.00
10/19/2021Morgan StanleyBoost TargetEqual Weight$107.00 ➝ $145.00
10/7/2021Leerink PartnersReiterated RatingBuy
10/6/2021HC WainwrightReiterated RatingBuy$135.00 ➝ $160.00
10/6/2021The Goldman Sachs GroupBoost TargetBuy$151.00 ➝ $170.00
10/5/2021MizuhoReiterated RatingBuy$137.00
10/5/2021Piper SandlerBoost TargetOverweight$140.00 ➝ $156.00
9/13/2021Cantor FitzgeraldBoost TargetOverweight$151.00 ➝ $165.00
8/10/2021UBS GroupDowngradeBuy ➝ Neutral$108.00 ➝ $109.00
7/16/2021Morgan StanleyBoost TargetEqual Weight$69.00 ➝ $107.00
7/12/2021MizuhoBoost TargetBuy$92.00 ➝ $134.00
7/8/2021HC WainwrightBoost TargetBuy$111.00 ➝ $135.00
7/7/2021CowenBoost TargetOutperform$90.00 ➝ $130.00
6/1/2021Cantor FitzgeraldBoost TargetOverweight$125.00 ➝ $140.00
5/28/2021MizuhoBoost TargetBuy$90.00 ➝ $92.00
5/18/2021Morgan StanleyLower TargetEqual Weight$76.00 ➝ $69.00
5/12/2021Leerink PartnersLower TargetOutperform$115.00 ➝ $105.00
5/11/2021MizuhoLower TargetBuy$98.00 ➝ $90.00
5/3/2021MizuhoLower TargetBuy$103.00 ➝ $98.00
4/26/2021MizuhoLower TargetBuy$103.00 ➝ $98.00
4/19/2021Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $76.00
3/11/2021UBS GroupInitiated CoverageBuy$108.00
3/2/2021MizuhoBoost TargetBuy$93.00 ➝ $103.00
3/1/2021Piper SandlerBoost TargetOverweight$90.00 ➝ $110.00
2/5/2021William BlairReiterated RatingBuy
1/19/2021MizuhoLower Target$100.00 ➝ $93.00
1/19/2021HC WainwrightLower TargetBuy$121.00 ➝ $111.00
12/29/2020Cantor FitzgeraldBoost TargetOverweight$109.00 ➝ $115.00
12/16/2020Morgan StanleyBoost TargetEqual Weight$63.00 ➝ $73.00
12/15/2020HC WainwrightInitiated CoverageBuy$121.00
12/7/2020Leerink PartnersBoost TargetOutperform$85.00 ➝ $120.00
11/13/2020MizuhoBoost TargetBuy$82.00 ➝ $100.00
10/13/2020WedbushBoost TargetOutperform$96.00 ➝ $99.00
10/13/2020Morgan StanleyBoost TargetEqual Weight$57.00 ➝ $63.00
8/24/2020Morgan StanleyLower TargetEqual Weight$60.00 ➝ $57.00
8/10/2020William BlairReiterated RatingBuy
7/15/2020Morgan StanleyBoost TargetEqual Weight$50.00 ➝ $60.00
6/26/2020MizuhoInitiated CoverageBuy$85.00
6/23/2020Cantor FitzgeraldBoost TargetOverweight$82.00 ➝ $109.00
6/18/2020WedbushBoost TargetOutperform$74.00 ➝ $94.00
6/15/2020CowenBoost TargetOutperform$60.00 ➝ $80.00
6/9/2020MizuhoReiterated RatingBuy$53.00 ➝ $85.00
5/20/2020MizuhoReiterated RatingBuy$53.00
5/11/2020Cantor FitzgeraldBoost TargetOverweight$75.00 ➝ $82.00
5/11/2020Morgan StanleyBoost TargetEqual Weight$46.00 ➝ $50.00
5/8/2020OppenheimerReiterated RatingHold$41.00
4/17/2020CowenInitiated CoverageOutperform$45.00
4/15/2020Morgan StanleyLower TargetEqual Weight$49.00 ➝ $46.00
3/31/2020OppenheimerLower TargetMarket Perform$48.00 ➝ $37.00
3/13/2020WedbushBoost TargetOutperform$73.00 ➝ $78.00
2/23/2020MizuhoReiterated RatingBuy$58.00
2/10/2020The Goldman Sachs GroupLower TargetBuy$89.00 ➝ $76.00
2/10/2020OppenheimerDowngradeOutperform ➝ Market Perform$67.00 ➝ $51.00
2/5/2020MizuhoInitiated CoverageBuy$62.00
1/29/2020WedbushReiterated RatingBuy$75.00
12/23/2019Piper Sandler CompaniesReiterated RatingBuy$100.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 18 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 28 very positive mentions
  • 36 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 27 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 27 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Biohaven logo
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $36.26
Low: $34.46
High: $36.95

50 Day Range

MA: $47.56
Low: $35.34
High: $53.73

52 Week Range

Now: $36.26
Low: $26.80
High: $62.21

Volume

3,229,003 shs

Average Volume

1,130,245 shs

Market Capitalization

$3.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Biohaven?

The following Wall Street sell-side analysts have issued stock ratings on Biohaven in the last twelve months: Bank of America Co., Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, TD Cowen, UBS Group AG, and William Blair.
View the latest analyst ratings for BHVN.

What is the current price target for Biohaven?

0 Wall Street analysts have set twelve-month price targets for Biohaven in the last year. Their average twelve-month price target is $63.00, suggesting a possible upside of 73.7%. Piper Sandler has the highest price target set, predicting BHVN will reach $76.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $54.00 for Biohaven in the next year.
View the latest price targets for BHVN.

What is the current consensus analyst rating for Biohaven?

Biohaven currently has 13 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHVN will outperform the market and that investors should add to their positions of Biohaven.
View the latest ratings for BHVN.

What other companies compete with Biohaven?

Other companies that are similar to Biohaven include Moderna, Viatris, Summit Therapeutics, Genmab A/S and Dr. Reddy's Laboratories. Learn More about companies similar to Biohaven.

How do I contact Biohaven's investor relations team?

Biohaven's physical mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company's listed phone number is 203-404-0410 and its investor relations email address is [email protected]. The official website for Biohaven is www.biohavenpharma.com. Learn More about contacing Biohaven investor relations.